Background Angiography and embolization (AE) is a lifesaving, high radiation dose procedure for treatment of abdominal arterial hemorrhage (AAH). Interventional radiologists have utilized pre-procedure CT angiography (CTA) and newer fluoroscopic systems in an attempt to reduce radiation dose and procedure time. Purpose To study the factors contributing to the radiation dose of AE for AAH and to compare to the reference standard. Materials and methods This retrospective single-centre observational cohort study identified 154 consecutive AE procedures in 138 patients (median age 65 years; interquartile range 54–77; 103 men) performed with a C-arm fluoroscopic system (Axiom Artis DTA or Axiom Artis Q (Siemens Healthineers)), between January 2010 and December 2017. Parameters analysed included: demographics, fluoroscopy system, bleeding location, body mass index (BMI), preprocedural CT, air kerma-area product (PKA), reference air kerma (Ka,r), fluoroscopy time (FT) and the number of digital subtraction angiography (DSA) runs. Factors affecting dose were assessed using Mann–Whitney U, Kruskal–Wallis one-way ANOVA and linear regression. Results Patients treated with the new angiographic system (NS) had a median PKA, median Ka,r, Q3 PKA and Q3 Ka,r that were 74% (p < 0.0005), 66%(p < 0.0005), 55% and 52% lower respectively than those treated with the old system (OS). This dose reduction was consistent for each bleeding location (upper GI, Lower GI and extraluminal). There was no difference in PKA (p = 0.452), Ka,r (p = 0.974) or FT (p = 0.179), between those who did (n = 137) or did not (n = 17) undergo pre-procedure CTA. Other factors significantly influencing radiation dose were: patient BMI and number of DSA runs. A multivariate model containing these variables accounts for 15.2% of the variance in Ka,r (p < 0.005) and 45.9% of the variance of PKA (p < 0.005). Conclusion Radiation dose for AE in AAH is significantly reduced by new fluoroscopic technology. Higher patient body mass index is an independent key parameter affecting patient dose. Radiation dose was not influenced by haemorrhage site or performance of pre-procedure CTA.

Background: This systematic review and meta-analysis compares long-term outcomes follow-up data comparing drug-eluting balloons (DEBs) and drug-eluting stents (DESs) in interventional treatment of small coronary artery disease (<3 mm). Methods: A systematic review was undertaken along with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The primary outcome was 1–3-year performance of DEB versus DES in major adverse cardiac events. Secondary outcomes include all-cause mortality, MI, cardiac death, vessel thrombosis, major bleeding, target vessel revascularisation and target lesion revascularisation. Two independent reviewers extracted data. All outcomes used the Mantel–Haenszel and random effects models. ORs are presented with a 95% CI. Results: Of 4,661 articles, four randomised control trials were included (1,414 patients). DEBs demonstrated reduced rates of non-fatal MI at 1 year (OR 0.44; 95% CI [0.2–0.94]), and BASKET-SMALL 2 reported a significant reduction in 2-year bleeding rates (OR 0.3; 95% CI [0.1–0.91]). There was no significant difference in all other outcomes. Conclusion: Long-term follow-up of DEB and DES use in small coronary arteries demonstrates DEBs be comparable with DESs in all outcomes at 1, 2 and 3 years of follow-up. A significant reduction was found in rates of non-fatal MI at 1 year in the DEB arm, and a reduction in major bleeding episodes at 2 years in the BASKET-SMALL 2 trial. These data highlight the potential long-term utility of novel DEBs in small coronary artery disease revascularisation.

Background Optimisation of low-density lipoprotein cholesterol (LDL-C) targets is one component of cardiac rehabilitation (CR). The 2019 European Society of Cardiology (ESC) guidelines recommend lower LDL-C targets than those released in 2016. Aims To determine the proportion of patients who met 2019 LDL-C targets and compare these to international standards; examine the effect of the introduction of the recent ESC guidelines on target achievement. Examine the choice of lipid lowering therapy (LLT) used in our cohort. Methods Retrospective chart review of 163 patients who attended CR in 2019. Baseline LDL-C levels were calculated where applicable. Targets achieved were compared with the contemporary ESC guidance. Required LLT was estimated for those who were unable to meet their LDL-C target. Results Overall, 96/163 (59%) patients met their absolute LDL-C targets, which was favourable when compared to international standards. Fewer patients treated using the 2019 ESC guidelines met their absolute, (63% (70/112) vs. 51% (26/51)), or relative LDL-C 43% (22/51) targets. A high intensity statin was prescribed in 63% (89/163) of patients and only 9% (5/163) patients were prescribed ezetimibe therapy; increased use of these agents may have led to a further 20% (33/162) of patients meeting their LDL-C targets. 13% (22/163) of patients likely require PCSK9i therapy. Conclusions Patients may be more likely to meet LDL-C targets while enrolled in CR compared to standard care. Following the introduction of lower absolute LDL-C targets and additional > 50% LDL-C reduction from baseline requirement, fewer patients are meeting the LDL-C targets set out in the 2019 ESC dyslipidaemia guidelines. Additionally, many patients are not on maximum statin therapy, ezetimibe is under-prescribed, and a guideline-reimbursement gap exists for those who require PCSK9i therapy. Supplementary information The online version contains supplementary material available at 10.1007/s11845-021-02885-9.

central death notification and publicly accessible online death notifications. Proximity from home address to the nearest PPCI centre was determined using Google Maps. Statistical analyses were performed using Stata. Results 7,486 STEMI patients were identified from January 2013 -March 2018. 6,612 were included in the analysis. Minimum follow up was 3 years, median follow up was 5.5 years. 4,040 received timely PPCI, 2,162 delayed PPCI, 335 t-PA. Baseline characteristics are shown in table 1. There was no difference in survival between the timely PPCI (84.7%) and t-PA groups (84.2%) (HR 0.93, 95%CI 0.71-1.25; Log-Rank p=0.62). There was increased mortality in the delayed PPCI (80.6%) in comparison with both timely PPCI (HR 1.5, 95%CI 1.16-1.49; Log-Rank p<0.000) and t-PA groups (HR 1.23, 95%CI 0.93-1.66; Log-Rank p=0.16), figure 1, 2. Conclusion Patients who were treated with a pharmaco-invasive strategy had lower all-cause mortality on long term follow up versus those who received PPCI outside of the target treatment window. Given the high proportion of patients who received delayed PPCI (33%), consideration should be given to expanding a pharmaco-invasive approach to patients who are unlikely to receive timely PPCI.

Introduction There has been a significant increase in Interventional Cardiology (IC) procedures over last few decades across the globe. The introduction of newer techniques and procedure types in IC has contributed to an overall increase in radiation exposure to both operators and patients alike. Unlike diagnostic imaging, IC procedures are heterogeneous and vary in their complexity based on a myriad of factors, such as patient disease characteristics, anatomy, nature of lesions and operator technique. Purpose The aim of the study is to evaluate the demographic and procedural characteristics associated with increased radiation dose. Limited studies exist on the impact of demographic and procedural characteristics on cumulative radiation dose. Methods Single-centre retrospective observational study of elective Percutaneous Coronary Intervention (PCI) patients from October 2018 to December 2018 in a 24/7 Irish pPCI centre. Patient level data including weight, height, demographic and procedural characteristics were collected for 65 consecutive elective PCI cases. Radiation exposure metrics, including Kerma Area Product (Pka), Reference Air Kerma (Ka,r) and Fluoroscopy Time (FT), were also collected. A Mann-Whitney U Test was used to assess for differences in radiation exposure between groups and a multivariate regression analysis was performed in order to identify those variables which contributed to radiation exposure. Results Median total radiation exposure for our cohort was (Q1–3) -Pka 109 (61–154) Gy·cm2, Ka,r 1746 (1,082–2,530)mGy and FT 16 (10–25)mins. Males (n=48) had a significantly higher radiation exposure Pka 126 (84–171) vs 56 (27–114)Gy·cm2 p=0.001; Ka,r 2094 (1256–2936) mGy p=0.006) than females. Those who underwent femoral access had significantly lower radiation exposure (Pka 50 (38–77) vs 114 (63–158) Gy·cm2 p=0.019; Ka,r (897 (725–1094) vs 2020 (1092–2618) mGy; p=0.018) when compared to radial access. Increasing body mass index (BMI) (p=0.03), multi vessel PCI (p=0.001) and the use of a “sheathless” technique (p=0.029) were associated with increasing radiation exposure (r2=0.630 Pka; Ka,r r2=0.611). Stent characteristics and all other clinical risk factors (HTN, smoking, DM, renal impairment, previous PCI) had no significant impact on radiation exposure. Conclusion Radiation exposure during IC in our cohort was within the range of most European Diagnostic Reference Levels (DRL's). Increased BMI and male gender were associated with increased radiation exposure. Procedural characteristics such as radial access, multi vessel PCI and the use of sheathless technique were independently associated with increasing radiation exposure. We recommend dose documentation of all procedures for these patients to avoid radiation hazards; with periodic assessment of statistical dose recording and planned follow up. Regression analysis Funding Acknowledgement Type of funding source: None